Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 600 participants.

Also called NCT02233790

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02233790
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02233790. Randomized; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI
Condition
No-Reflow Phenomenon
Intervention (Drug)
Ticagrelor
Intervention (Drug)
Clopidogrel
Lead sponsor
First Hospital of China Medical University (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02233790
Content hash
5c3e9103f0ed4e4474466967f4240760e949f2b2b3defa1e5a6ab5cc7329db0c